EP
Therapeutic Areas
Vyripharm Biopharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| VYR-206 | Neurological Disorders (Diagnostic) | Pre-clinical |
| Antiviral Theranostic Program | COVID-19 / Viral Infections | Pre-clinical |
| Oncology Programs | Oncology | Pre-clinical |
| Hemp/Cannabis Standardization | Agribiopharmaceuticals Testing/Classification | Research |
Leadership Team at Vyripharm Biopharmaceuticals
EJ
Elias Jackson Jr., Ph.D.
Director of Government and Scientific Affairs
PC
Phil Clarke
Chief Business Officer